Spend any time in the pharma sector right now and it can feel as though GenAI in pharma is being talked about as a kind of coming tide: vast, inevitable, and capable of reshaping everything it touches. Discovery, development, medical affairs, commercial execution all are being reimagined through an AI lens. And in many respects, that excitement is justified.
But as a healthcare communicator, beneath the headlines about speed, scale and productivity, I look for answers to a more nuanced question. As GenAI becomes embedded across the pharna sector, where will it truly transform how pharma works, and where will human judgement, creativity and empathy remain relevant and I hope essential?
The parts of pharma that will change fastest with GenAI
The clearest impact of GenAI in pharma is likely to be felt in areas where the sector already grapples with complexity, volume and inefficiency. Drug discovery is the obvious example. Here, AI promises to dramatically accelerate early-stage research by sifting through enormous biological datasets, generating hypotheses at scale, and proposing molecules or protein structures that humans might never intuitively design. The real shift isn’t just speed, but the ability to pursue far more ideas, earlier, and discard unpromising ones sooner.
Clinical development, is another area ripe for reinvention. In pharma, GenAI can support smarter trial design, optimise inclusion criteria, improve patient identification, and surface signals more quickly. None of this removes the need for clinical expertise, but it does reduce the friction and waste that have historically inflated timelines and costs.
Elsewhere, the impact is more quietly profound. In medical, regulatory and safety functions, GenAI excels at synthesising evidence, drafting structured documentation and keeping pace with evolving guidance. Tasks that once absorbed huge amounts of expert time can now be partially automated, freeing specialists to focus on interpretation and decision-making rather than assembly.
Commercially, too, AI is redefining what “personalisation” really means. With GenAI, pharma can analyse behaviour and context at a level of granularity that was previously impractical, adapting insights and content across markets and channels without proportionally increasing resource. The system becomes more responsive, more tailored, and on the surface at least more efficient.
But healthcare is more than an inanimate system. It’s rich with human experience.
And this is where the limits of GenAI begin to matter.
Pharma does not operate in a neutral environment. It operates in the context of illness, uncertainty, fear, hope and trust. These are not abstract variables; they are lived experiences. And while AI is increasingly proficient at identifying patterns in data, it struggles with meaning, with understanding why people behave as they do, or how they feel about the choices put in front of them.
Strategic judgement remains a fundamentally human domain. GenAI can generate options and model scenarios, but it cannot own the consequences of a decision. Choosing which science or innovation to back, when to stop a scientific programme, or how to balance commercial ambition with patient needs involves values, ethics and accountability. These are leadership challenges.
The same is true for insight. Understanding patients and clinicians is not simply a matter of analysing inputs. It requires listening, interpretation and empathy. Why does a patient disengage from treatment? Why does a clinician resist a guideline, or react sceptically to new data? These subtleties often sit between the lines of surveys and datasets, in tone, context and experience. Human understanding, grounded in genuine empathy, remains irreplaceable.
Creativity is another example. GenAIcan generate content at scale, but in healthcare communication creativity is never about ‘more is more’ or volume of content. It is about making sense of things — helping people understand complex science, navigate uncertainty and feel confident about their decisions. This kind of storytelling is rooted in sound judgement and emotional intelligence.
Finally, there is trust. Healthcare depends on it. As AI becomes more embedded in pharma’s operations, the challenge of ethical stewardship grows with it. How transparently are companies using AI? How are they managing biases and communicating limitations? Responding to scepticism, concern or misinformation requires credibility and moral clarity, qualities that are built through human relationships, certainly not algorithms.
Refocusing on what cannot be automated
Seen this way, GenAI’s ultimate impact on pharma is the time that it gives back, reducing the time people spend compiling, summarising and administrating, towards the things that matter most: thinking, interpreting, connecting and deciding. The true risk is that organisations forget to protect and invest in the human skills that cannot be automated.
The pharma organisations that are already ahead and likely to succeed in the GenAI era are those that recognise this distinction, using AI aggressively where it adds speed and scale and deliberately making space for human judgement, creativity and empathy where trust and meaning are at stake.
As AI takes on more of the heavy lifting inside pharma, the role of human-centred insight and communication becomes not less important, but more so. In healthcare, after all, efficiency is important, but understanding and engaging with people is existential.
Photograph by Fran Alarcon on Unsplash
